$SABS News

SAB Biotherapeutics Receives Breakthrough T1D Grant To Advance SAB-142 Study In Newly Diagnosed Type 1 Diabetes

Barclays Initiates Coverage On SAB Biotherapeutics with Overweight Rating, Announces Price Target of $13

Chardan Capital Maintains Buy on SAB Biotherapeutics, Raises Price Target to $16

Leerink Partners Maintains Outperform on SAB Biotherapeutics, Raises Price Target to $12

HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Maintains $10 Price Target

Citigroup Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

Jefferies Initiates Coverage On SAB Biotherapeutics with Buy Rating, Announces Price Target of $11

We Think SAB Biotherapeutics (NASDAQ:SABS) Needs To Drive Business Growth Carefully

SAB Biotherapeutics Inc (SABS) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Rising ...

SAB Biotherapeutics Q1 Earnings Call Highlights

SAB Biotherapeutics (NASDAQ:SABS) Reports Q1 2026 Miss as Clinical Progress and Extended Cash Runway Through 2028 Take Center Stage

HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

Full Transcript: SAB Biotherapeutics Q1 2026 Earnings Call

SAB Biotherapeutics Q1 EPS $(0.35) Misses $(0.20) Estimate.

Rodman & Renshaw Reiterates Buy on SAB Biotherapeutics, Maintains $13 Price Target

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

SAB Biotherapeutics Looks Undervalued If SAB-142 Delivers In Type 1 Diabetes